145 related articles for article (PubMed ID: 10052059)
1. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
Lefebvre HP; Laroute V; Concordet D; Toutain PL
J Vet Intern Med; 1999; 13(1):21-7. PubMed ID: 10052059
[TBL] [Abstract][Full Text] [Related]
2. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
Toutain PL; Lefebvre HP; Laroute V
J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
Kitagawa H; Eguchi T; Kitoh K; Ohba Y; Kondo M; Nakano M; Sasaki Y
J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
[TBL] [Abstract][Full Text] [Related]
6. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
King JN; Strehlau G; Wernsing J; Brown SA
J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
[TBL] [Abstract][Full Text] [Related]
7. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.
Macdonald NJ; Sioufi A; Howie CA; Wade JR; Elliott HL
Br J Clin Pharmacol; 1993 Sep; 36(3):205-9. PubMed ID: 9114905
[TBL] [Abstract][Full Text] [Related]
8. Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.
Elung-Jensen T; Heisterberg J; Sonne J; Strandgaard S; Kamper AL
Eur J Clin Pharmacol; 2005 Apr; 61(2):87-96. PubMed ID: 15761754
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles.
Okuyama CE; Mendes GD; Faro R; Rezende VM; Lagos RM; Astigarraga RE; Antunes E; De Nucci G
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):290-5. PubMed ID: 17324140
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
[TBL] [Abstract][Full Text] [Related]
11. Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.
Fusellier M; Desfontis JC; Madec S; Gautier F; Marescaux L; Debailleul M; Gogny M
J Vet Pharmacol Ther; 2005 Dec; 28(6):581-6. PubMed ID: 16343292
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Lefebvre HP; Jeunesse E; Laroute V; Toutain PL
J Vet Intern Med; 2006; 20(3):499-507. PubMed ID: 16734081
[TBL] [Abstract][Full Text] [Related]
13. An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
Kitagawa H; Ohba Y; Kuwahara Y; Ohne R; Kondo M; Nakano M; Sasaki Y; Kitoh K
J Vet Med Sci; 2003 Jun; 65(6):701-6. PubMed ID: 12867730
[TBL] [Abstract][Full Text] [Related]
14. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
Waldmeier F; Kaiser G; Ackermann R; Faigle JW; Wagner J; Barner A; Lasseter KC
Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180
[TBL] [Abstract][Full Text] [Related]
15. High serum enalaprilat in chronic renal failure.
Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
[TBL] [Abstract][Full Text] [Related]
16. Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
Levens NR
Arch Int Pharmacodyn Ther; 1988; 296():131-43. PubMed ID: 2853611
[TBL] [Abstract][Full Text] [Related]
17. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog.
Lefebvre HP; Schneider M; Dupouy V; Laroute V; Costes G; Delesalle L; Toutain PL
J Vet Pharmacol Ther; 1998 Dec; 21(6):453-61. PubMed ID: 9885968
[TBL] [Abstract][Full Text] [Related]
18. Development of a new benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for treatment of heart failure in dogs.
Qian M; Chen T; Zhou D; Zhang Z; Zhang Q; Tang S; Xiao X
J Vet Pharmacol Ther; 2016 Feb; 39(1):98-101. PubMed ID: 26228576
[TBL] [Abstract][Full Text] [Related]
19. Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function.
Hersh AD; Kelly JG; Laher MS; Carmody M; Doyle GD
J Cardiovasc Pharmacol; 1996 Jan; 27(1):7-11. PubMed ID: 8656661
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product.
Kelers K; Devi JL; Anderson GA; Zahra P; Vine JH; Whittem T
Aust Vet J; 2013 Aug; 91(8):312-9. PubMed ID: 23889096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
